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Abstract: BACKGROUND Tibial shaft fractures (TSFs) are among the most common long bone injuries
often resulting from high-energy trauma. To date, musculoskeletal complications such as fracture-related
infection (FRI) and compromised fracture healing following fracture fixation of these injuries are still
prevalent. The relatively high complication rates prove that, despite advances in modern fracture care,
the management of TSFs remains a challenge even in the hands of experienced surgeons. Therefore,
the Fracture-Related Outcome Study for operatively treated Tibia shaft fractures (F.R.O.S.T.) aims at
creating a registry that enables data mining to gather detailed information to support future clinical
decision-making regarding the management of TSF’s. METHODS This prospective, international, mul-
ticenter, observational registry for TSFs was recently developed. Recruitment started in 2019 and is
planned to take 36 months, seeking to enroll a minimum of 1000 patients. The study protocol does not
influence the clinical decision-making procedure, implant choice, or surgical/imaging techniques; these
are being performed as per local hospital standard of care. Data collected in this registry include injury
specifics, treatment details, clinical outcomes (e.g., FRI), patient-reported outcomes, and procedure- or
implant-related adverse events. The minimum follow up is 12 months. DISCUSSION Although over the
past decades, multiple high-quality studies have addressed individual research questions related to the
outcome of TSFs, knowledge gaps remain. The scarcity of data calls for an international high-quality,
population-based registry. Creating such a database could optimize strategies intended to prevent severe
musculoskeletal complications. The main purpose of the F.R.O.S.T registry is to evaluate the association
between different treatment strategies and patient outcomes. It will address not only operative techniques
and implant materials but also perioperative preventive measures. For the first time, data concerning sys-
temic perioperative antibiotic prophylaxis, the influence of local antimicrobials, and timing of soft-tissue
coverage will be collected at an international level and correlated with standardized outcome measures in
a large prospective, multicenter, observational registry for global accessibility. TRIAL REGISTRATION
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Abstract
Background: Tibial shaft fractures (TSFs) are among the most common long bone injuries often resulting from
high-energy trauma. To date, musculoskeletal complications such as fracture-related infection (FRI) and
compromised fracture healing following fracture fixation of these injuries are still prevalent. The relatively high
complication rates prove that, despite advances in modern fracture care, the management of TSFs remains a
challenge even in the hands of experienced surgeons. Therefore, the Fracture-Related Outcome Study for
operatively treated Tibia shaft fractures (F.R.O.S.T.) aims at creating a registry that enables data mining to gather
detailed information to support future clinical decision-making regarding the management of TSF’s.
Methods: This prospective, international, multicenter, observational registry for TSFs was recently developed.
Recruitment started in 2019 and is planned to take 36 months, seeking to enroll a minimum of 1000 patients. The
study protocol does not influence the clinical decision-making procedure, implant choice, or surgical/imaging
techniques; these are being performed as per local hospital standard of care. Data collected in this registry include
injury specifics, treatment details, clinical outcomes (e.g., FRI), patient-reported outcomes, and procedure- or
implant-related adverse events. The minimum follow up is 12 months.
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Discussion: Although over the past decades, multiple high-quality studies have addressed individual research
questions related to the outcome of TSFs, knowledge gaps remain. The scarcity of data calls for an international
high-quality, population-based registry. Creating such a database could optimize strategies intended to prevent
severe musculoskeletal complications. The main purpose of the F.R.O.S.T registry is to evaluate the association
between different treatment strategies and patient outcomes. It will address not only operative techniques and
implant materials but also perioperative preventive measures. For the first time, data concerning systemic
perioperative antibiotic prophylaxis, the influence of local antimicrobials, and timing of soft-tissue coverage will be
collected at an international level and correlated with standardized outcome measures in a large prospective,
multicenter, observational registry for global accessibility.
Trial registration: ClinicalTrials.gov: NCT03598530.
Keywords: Fracture-related infection, Tibial shaft fracture, Fracture fixation, Complications, Nonunion, Fracture,
Infection, Registry
Background
Tibial shaft fractures (TSFs) are among the most com-
mon long bone injuries [1]. Their incidence has been re-
ported on several occasions and varies between 8.1 and
37.0 per 100,000 persons/year, with a decrease over re-
cent years [1–3]. Over 15% of tibia fractures are classi-
fied as open, representing the most common open long
bone fracture [4, 5]. This is one of the reasons why mus-
culoskeletal complications such as fracture-related infec-
tion (FRI) and compromised fracture healing remain
prevalent with these types of injuries. Currently, the inci-
dence of FRI ranges from 1%, following operative fix-
ation of closed low-energy fractures [6], to 25–30% in
complex open tibia fractures [5]. Nonunion rates vary
from 3 to 17% [7–9]. Furthermore, annual reoperation
rates following the operative treatment of TSFs have
been reported to vary between 12 and 44% [10]. These
high complication rates suggest that despite advances in
modern fracture care, treatment of TSFs poses a chal-
lenge even for experienced surgeons.
Although several high-quality studies have already ad-
dressed individual research questions, knowledge gaps
remain. Hence, the aim of the Fracture-Related Out-
come Study for operatively treated Tibia shaft fractures
(F.R.O.S.T.) is to create a registry that allows data min-




The registry’s main objective is to collect data on the op-
erative treatment and outcome of TSFs in patients aged
≥18 years in an international and multicenter setting.
Specifically, this registry aims to:
 Increase knowledge and evidence with respect to the
epidemiology and treatment concepts of TSFs
worldwide by collecting prospective data in a
structured and systematic manner.
 Identify risk factors (e.g., injury, patient, or
treatment) for favorable and unfavorable outcomes
and complications.
 Allow data mining to gather evidence to optimize
the clinical decision-making process, particularly to
(i) develop strategies that intend to prevent muscu-
loskeletal complications and (ii) generate hypotheses
for future studies.
Study design
This is a prospective, international, multicenter, observa-
tional registry. Patient treatment is being performed ac-
cording to the local standard of care (routine), that is,
the study protocol (supplementary material) does not in-
fluence the clinical decision-making procedure or mate-
rials or surgical/imaging techniques. The sites that are
currently included are summarized in Table 1.
Participants
Sample size estimation
Owing to the exploratory nature of this registry, there is
no formal sample size calculation. Approximately 1000
tibial shaft fractures are expected to be included in the 3
years enrollment period. A sample size of 1000 will allow
the identification of infrequent adverse events (AEs) as
well as rare treatment concepts. The following inclusion
and exclusion criteria are specified:
Inclusion criteria
1. Aged ≥18 years at the time of the injury.
2. The diagnosis of a primary TSF, a fracture type 42,
according to the Arbeitsgemeinschaft für
Osteosynthesefragen (AO)/Orthopaedic Trauma
Association (OTA) Fracture and Dislocation
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Classification (Fig. 1), that will be treated
operatively as part of the standard of care.
3. Informed consent will be obtained based on:
a. The ability of the patient or an assigned
representative to understand the content of the
patient information/Informed Consent Form (ICF).
b. Signed and dated Institutional Review Board
(IRB)/Ethics Committee (EC)-approved written
informed consent.
Exclusion criteria
1. Pathological fractures caused by malignancy.
2. Patients participating in any other medical device or
medicinal product study within the previous month
that could influence the results of the present study.
3. Patients who cannot provide independent written
informed consent unless defined, and IRIR/EC-
approved procedures for consenting such
vulnerable patients are in place.
Procedures
Recruitment
First, the investigator or another appropriately trained
member of the research team at the study site identifies
all eligible patients. These patients should meet all inclu-
sion criteria and none of the exclusion criteria. Next,
they inquire about the patient’s interest in participating
in this study. If the patient wishes to participate, a legally
eligible member of the research team goes through the
informed consent process with the patient, explaining
the study’s purpose, procedures, risk/benefits, alterna-
tives to participation, and data protection. Each patient
who chooses to participate signs and dates an ICF. All
consenting patients are allocated a unique patient trial
Table 1 Sites currently included in the Fracture-Related Outcome Study for operatively treated Tibia shaft fractures (F.R.O.S.T.)
Department of Trauma Surgery, University Hospitals Leuven, Leuven, Belgium PI (PCI): Willem-Jan
Metsemakers
Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital Muenster, Muenster, Germany PI (Co-PCI): Michael
Raschke
Department of Trauma Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands PI (Co-PCI): Michael H. J.
Verhofstad
Department of Orthopaedic and Trauma Surgery, University Hospital Basel, Basel, Switzerland PI Mario Morgenstern
Division of Orthopaedics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg Hospital,
Cape Town, South Africa
PI Nando Ferreira
Department of General Trauma and Reconstructive Surgery, University Hospital, LMU Munich, Munich, Germany PI Christian
Kammerlander
Department of Orthopaedic Surgery and Rehabilitation, Vanderbilt University Medical Center, Nashville, TN,
United States of America
PI William T. Obremskey
Department of Orthopedic Surgery, NYU Langone Orthopedic Hospital, New York, NY, United States of America PI Kenneth A. Egol
Department of Orthopaedic Surgery, NYU Langone Orthopedic Hospital and Jamaica Hospital Medical Center,
New York, NY, United States of America
PI Sanjit Konda
Department of Orthopaedic Surgery, Korea University College of Medicine, Guro Hospital, Guro-gu, Seoul, Repub-
lic of Korea
PI Jong-Keon Oh
Department of Orthopaedic Surgery, Sengkang General Hospital, Singapore PI Wong Merng Koon
Department of Trauma, UniversitätsSpital Zürich, University of Zurich, Zurich, Switzerland PI Hans-Christoph Pape
Academic Department of Trauma and Orthopaedics, School of Medicine, University of Leeds, Leeds General
Infirmary, Leeds, United Kingdom (Planned New Site)
PI Peter V. Giannoudis
Department of Orthopaedics and Traumatology, University Medical Center, Johannes Gutenberg-University,
Mainz, Germany (Planned New Site)
PI Eric Hanke
Department of Orthopaedics and Traumatology, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong
Kong (Planned New Site)
PI Christian Fang
Department of Surgery, Franciscus Gasthuis en Vlietland Hospital, Rotterdam, The Netherlands (Planned New Site) PI Taco M. A. L. Klem
Department of Orthopedics, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands (Planned New Site) PI Kirsten Kortram
Site selection was based on a world-wide open call by the AO Foundation. It was decided that sites should be included from different parts of the world. The
following criteria were developed during the decision-making process:
1. A site should be able to recruit a minimum number of patients within the planned recruitment time (a minimum of 65–75 patients per year).
2. A site should make sure that patients are in follow up for a minimum time of 1 year.
3. Sites must be able to anonymize their clinical data (e.g., radiological images).
4. Sites are able to plan patient visits as per standard of care at the site.
5. Sites should agree to the administrative conditions (reimbursement, contracts) and receive approval from their local ethical committee.
6. Sites should be able to perform registry related documentation
PCI Principal Coordinating Investigator, co-PCI co-Principal Coordinating Investigator, PI local Principal Investigator
Metsemakers et al. BMC Musculoskeletal Disorders           (2021) 22:57 Page 3 of 10
number. A protocol deviation is documented for patients
found ineligible after treatment, indicating which inclu-
sion/exclusion criterion (or criteria) was (or were)
violated.
The follow-up (FU) population will consist of patients
who have signed informed consent, are eligible (i.e.,
meet all inclusion and none of the exclusion criteria),
and have commenced treatment (i.e., definitive treat-
ment). Recruitment is planned to take 36months to en-
roll a minimum of 1000 patients. An evaluation will take
place at the end of this period. If deemed necessary, due
to a high percentage of dropouts for example, the study
period may be extended.
Baseline parameters
During their first visit to the emergency department or ur-
gent care center, patients are assessed for eligibility. If in-
formed consent is obtained, parameters regarding
demographics, medical history, and injury are collected.
Radiographic images and/or clinical pictures are taken as per
local standard of care (routine) procedures. Demographic
data, such as age, sex, height, weight, and ethnicity, are re-
corded. Medical history is documented in sufficient detail to
calculate the Charlson Comorbidity Index, which has been
designed and validated to classify prognostic comorbidity in
longitudinal studies [11, 12]. Its prognostic accuracy has also
been validated for a combined age-comorbidity index [13].
The recorded information includes the history of cardiovas-
cular diseases, asthma, chronic lung disease, diabetes, renal
disease, chronic liver disease, gastric or peptic ulcers, cancer,
dementia, rheumatic or connective tissue disease, immuno-
compromised status [human immunodeficiency virus and/or
others], and American Society of Anesthesiologists scores.
Information on medication history comprises the use
of antibiotics, osteoporosis treatment, chronic use of an-
algesics and/or corticosteroids, and alcohol and drug in-
take. Information concerning the injury includes which
side of the body the fracture is located on, high- or low-
energy trauma, injury severity score, and fracture classifi-
cation according to the AO/OTA fracture and dislocation
classification [14]. Detailed information on additional
fractures of the lower extremities both ipsilateral and
Fig. 1 AO/OTA tibial shaft fracture (TSF) classification
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contralateral will be collected. Furthermore, details of
additional injuries will also be collected (e.g. cerebral,
spine, thorax, abdomen, pelvis, upper extremity). Soft-
tissue injury is to be classified according to Tscherne [15]
for closed fractures and according to Gustilo-Anderson
[16] and the OTA Open Fracture Classification [17] for
open fractures. Concomitant fractures of the tibia or fib-
ula are to be classified according to the AO/OTA fracture
and dislocation classification [14].
Interventions and study procedures
Patients will undergo fracture fixation using osteosynth-
esis, including single- or multiple-staged procedures
(e.g., initial external fixation with later conversion to in-
ternal fixation). The operative treatment for TSFs in
adults mainly depends on the fracture characteristics
and extent of the soft tissue damage and is to be per-
formed according to the standard (routine) care proce-
dures based on the individual clinician’s judgment and
patient characteristics. Neither specific treatment nor
specific time points for FU visits are dictated for registry
purposes.
Registry-related assessments will include radiographic
evaluations, performed by the treating surgeon at the
treatment visit and at defined time points after treatment,
following each site’s standard (routine) visit schedule for
up to 36months. Radiographic images and/or clinical pic-
tures will be stored to enable future ad-hoc analysis after
de-identification. If patients are unable to attend the last
planned FU visit, they will be contacted by e-mail or
phone to document the final outcomes, especially patient-
reported outcomes (PROs) and complications not previ-
ously captured. The planned registry schedule is displayed
in Table 2 over the 36-months FU visit period.
Outcome measures
The data collected in this registry will include treatment
details, clinical outcomes, PROs, and procedure- or
implant-related AEs. Documentation of treatment details
will comprise information about the time from injury to
Table 2 Registry schedule for the Fracture-Related Outcome Study for operatively treated Tibia shaft fractures (F.R.O.S.T.)
Baseline Treatment Post-treatment visit
1a
Post-treatment visit 2a Post-treatment visit 3a Additional Post-
treatment visit(s)a
– Day 0 6 weeks (target 42
days: range 14 to
105)
6months (target 183
days; range 106 to 260)
12months (target 365

















X X X X X
PROMIS: Physical
Function
X X X X X
PROMIS: Pain
Interference
X X X X
Pain numeric
rating scale (NRS)
X X X X
Complications X X X X
Images and/or other
clinical pictures
Xd Xd Xd Xd Xd Xd
a If a patient does not visit at the specified time point, the visits will be assigned according to the specified rules. Additional postoperative visits may take place
up to 36months after day 0
b Informed consent may occur after treatment under certain circumstances (see details in section 10). No data can be collected in the eCRF prior to consent
c Treatment may occur on the same day as the baseline. Treatment of tibial fractures may require two or more stage-procedures (e.g., external fixation and
secondary internal fixation) performed on different days
d Images (X-ray images, CT scans, etc.) and clinical pictures are collected ONLY if they are taken as part of the standard of care (routine) procedures. All images
and photographs will be de-identified
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index surgery, duration of surgery, number of stages of
the procedure, skin preparation, tourniquet use, details
about debridement and irrigation, type of reduction/fix-
ation method, specifics related to the fixation devices
(e.g., material type, implant dimension), intraoperative
blood loss, as well as the use of local agents to promote
bone healing. Moreover, information relating to the peri-
operative use of either prophylactic or curative systemic
antibiotics and application of local antimicrobials will be
documented and entered in the database. Furthermore,
information pertaining to soft-tissue management will
be recorded, such as timing and details of wound clos-
ure, soft-tissue coverage, and flap type. For concomitant
fractures of the tibia or fibula, the treatment method will
be documented. If further treatments are performed dur-
ing the index surgery, these will also be captured.
Clinical outcome documentation will include time to
bone healing/union, the presence of malalignment, malro-
tation or malunion, and the time to full weight bearing.
Time to bone healing is defined as the time elapsed be-
tween definitive treatment and bony union. The healing
status assessment will be based on a combination of clin-
ical and radiological parameters, which will be judged by
the treating surgeon. Clinically, healing will be rated as
complete when the patient is able to walk without support
in the absence of pain or tenderness at the fracture site.
Radiologically, the modified RUST score [18] will be de-
termined by scoring each cortex on the anteroposterior
(AP) and lateral radiographs as 1 = no callus, 2 = callus
present, 3 = bridging callus, and 4 = remodeled, fracture
not visible. The modified RUST score is the sum of these
and therefore has a value from 4 to 16.
Malalignment, malrotation, and malunion will be de-
termined by the treating surgeon. Malalignment will be
measured on AP and lateral radiographs using the
method described by Freedman et al. [19]. An angulation
of > 5° in any plane is regarded as malalignment. Malro-
tation will be measured clinically and/or radiologically,
depending on the availability of rotational CT and the
local standard of care. A rotational deviation of > 10° is
regarded as malrotation [20]. Malunion denotes that
fracture-healing results in deformity corresponding to
one or a combination of the following: > 5° malalign-
ment, > 10° of malrotation, and/or a shortening of > 1
cm [20]. Time to full weight bearing is defined as the
time elapsed between definitive treatment and the treat-
ing surgeon allowing the patient to bear full weight on
the injured leg with or without any support. Global
health, pain interference, and physical function will be
documented using the corresponding domains of the
Patient-Reported Outcomes Measurement Information
System (PROMIS®) questionnaires. PROMIS® was estab-
lished in 2004 with funding from the National Institutes
of Health (NIH) as one of the NIH Roadmap initiatives
for Medical Research and provided standardized and val-
idated measures [21].
The questionnaires are designed to be completed by
the patients without assistance. However, we anticipate
that some patients may be unable to attend the planned
FU visit(s). In these cases, patients will be contacted by
e-mail or phone to document the outcome per interview.
Interviews have been shown to produce similar scores
compared to those obtained after completion of the
questionnaires by the patients themselves [22, 23].
Validated translations of PROMIS® are available in an
increasing number of languages. For this registry, only
sites for which validated language versions are available
will be asked to complete the forms. As other translations
become available, these will be implemented immediately
after notification of the respective IRB/EC.
The pre-injury status concerning global health and
physical function will be captured retrospectively at
baseline and entered in the database. The global health
assessment reflects an individual’s evaluation of their
physical, mental, and social health. In this registry, a
short form of 10 questions (v1.2) will be used. The pain
interference questionnaire covers pain interference with
physical, social, and recreational activities and will be
documented with a short form of 8 questions (v1.0 –
Pain Interference 8a). The physical function (mobility)
questionnaire assesses the patients’ ability to perform
various daily living activities, documented in a short
form of 10 questions (v2.0 – Physical Function 10b).
Pain will be documented on a numeric rating scale
(NRS) from 0 to 10 for the injured leg, the knee of the
injured leg, and the ankle of the injured leg. Procedure-
or implant-related adverse events, i.e., complications, will
only be documented for the injured tibia, but not for
concomitant fractures in the fibular, malleolar, or other
regions.
In addition to AEs entered via free text, some pre-
defined complications will be captured. Intraoperative
pre-defined complications include iatrogenic fracture, iat-
rogenic vessel damage, excessive bleeding, iatrogenic
nerve damage, and intraoperative resuscitation. Postopera-
tive pre-defined complications include compartment syn-
drome, FRI, nonunion, refracture/peri-implant fracture,
secondary loss of reduction, secondary displacement or
breakage of the fixation material, deep vein thrombosis,
pulmonary embolism, ongoing pain medication, or inabil-
ity to bear full weight 1 year after definitive treatment.
FRI will be diagnosed as defined in the recently pub-
lished consensus definition [24] and subsequent update
[25]. Additional contextual information will be collected
for all AEs and comprises the start date of the event, its
severity and seriousness, information about the related
additional treatment(s), date of recovery, and the event’s
outcome.
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Data collection and management
Data handling and protection will be conducted accord-
ing to the ISO 14155 guidelines, ICH-GCP, and applic-
able regulations. An electronic case report form (eCRF)
has been designed in REDCap Cloud (https://www.
redcapcloud.com/) to accommodate the registry’s spe-
cific features.
The REDCap Cloud is browser-based, metadata-
driven, state-of-the-art electronic data capture software.
Access to the eCRF is password-protected, and specific
functions are assigned. The eCRF is to be completed
promptly after a patient’s visit (i.e., 14 days after the oc-
currence of a documentable event).
During the site initiation visit and prior to recruiting
the first patient, the research team at each site under-
went a defined training program that includes explana-
tions on inclusion and exclusion criteria, registry
procedures, how to use the eCRF, and general aspects of
ISO 14155 and GCP. Monitoring visits are to be per-
formed on-site or remotely (via a web conference) as fre-
quently as required to guarantee the completeness and
accuracy of the information in the eCRF. Source data
and any other essential documents must be archived ac-
cording to the study site’s legal requirements. Clinical
study data (i.e., eCRF) and essential documents will be
archived by the sponsor according to the legal
requirements.
Premature termination
Due to the nature of the registry, no stopping rules have
been defined. All treatments will be per standard of care,
and no additional or investigational medical device or
medication will be administered during the investigation.
Patient participation in the study may end prematurely
for one of the following reasons:
 The patient withdraws informed consent
 Screening failure (patient not meeting the eligibility
criteria)
 Investigator’s discretion (e.g., patient noncompliance
with the registry plan)
 Sponsor’s decision
 Unknown/lost to FU
 Death
In the case of premature termination, detailed infor-
mation explaining the circumstances leading to termin-
ation will be obtained and recorded in the eCRF.
Reporting of adverse events
Due to the nature of the registry, immediate reporting of
AEs and serious AEs to the local EC/IRB is not required,
unless indicated otherwise by the local EC/IRB. The oc-
currence of AEs and severe AEs will be summarized in
annual reports and submitted to the EC/IRB, as
required.
Statistical analyses
As the registry aims are mainly descriptive and explora-
tory, patient characteristics and outcomes recorded at
the standard of care scheduled FU assessments will be
presented using simple summary statistics. Categorical
variables will be summarized using the frequency and
percentage for each category. Continuous variables will
be summarized using the mean, standard deviation, me-
dian, interquartile range, and the minimum and max-
imum values. Additionally, summary statistics will be
presented and stratified to clinically relevant categories,
including the type of treatment received. Complications
will be reported at both the patient and AE levels. Mul-
tiple events of the same type will be combined for each
patient. Upon calculating complication rates, the denom-
inator will be the total population size, irrespective of
dropouts during FU. All complication rates will be pre-
sented with 95% confidence intervals. In addition to
overall rates, complications will be presented according
to categories for various relevant parameters, such as
“action taken” (none/operative/nonoperative) or “out-
come” (in progress/without persistent damage/with per-
sistent damage/death). Patients with more than one
event of the same type will be presented according to
the most severe category.
To identify risk factors and evaluate specific research
questions, it is planned to perform further appropriate
statistics (e.g., multivariable analyses) if the volume and
quantity of the collected data allows this. Enrolled pa-
tients who withdraw from the study FU for any reason
(withdrawal of consent, death, loss to FU, etc.) will be
included in the analysis until the time at which they
withdrew.
Ethical considerations and dissemination
This is an observational study on tibia fractures, often
incurred through high-energy trauma such as road traf-
fic accidents. Consequently, vulnerable patients who re-
quire immediate and/or emergency treatment, present
with impaired decision-making capacity (temporarily or
permanently), or who are only able to give oral consent
may be included. In these cases, surrogate consent
(study protocol proof; page 29) will be obtained unless
otherwise indicated by the local EC/IRB and the patient’s
informed consent will be obtained as soon as possible.
This study has been registered in Clinical Trials.gov
under registration number NCT03598530. Ethics ap-
proval for this study was granted by the local EC or the
IRB from each of the currently participating sites prior
to patient enrollment. The results of this study will be
published in peer-reviewed journals and presented at
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different conferences. This study will be conducted fol-
lowing the ethical principles established in the Helsinki
Declaration updated in 2008.
Discussion
TSFs are common injuries that can be challenging to
treat due to the broad spectrum of fracture patterns,
often combined with soft-tissue injuries. Therefore, mus-
culoskeletal complications (i.e., FRI, nonunion) remain
common. These complications not only influence the
patient outcome but also place a cost burden on total
healthcare expenditure [26]. Although treatment strat-
egies have improved over recent years, complication
rates remain higher compared to those of other anatom-
ical locations and even compared to those related to
many other surgically-treated disease entities [5, 27]. A
better understanding of the epidemiology and pathogen-
esis of these complications is therefore essential because
it can lead to prevention rather than treatment strategies
[9].
Although high-quality studies have addressed ques-
tions related to the outcome of TSFs [28, 29], essential
knowledge gaps – specifically within the field of FRI –
remain. Multiple surveys indeed demonstrate a wide
variability in clinical practice related to the prevention of
musculoskeletal complications, especially in open frac-
tures [27, 30, 31]. Puetzler et al. stated that global het-
erogeneity exists among orthopedic trauma surgeons
concerning measures taken to prevent FRI [27]. This is
in line with the widespread opinion among orthopedic
trauma surgeons that adequate prevention guidelines
based on solid scientific evidence are currently lacking
[27].
One method for gathering more knowledge is the im-
plementation of a high-quality, international,
population-based registry. During the past decades,
interest in orthopedic registries has grown exponentially
[32]. Wennergren et al. recently published results from
the Swedish Fracture Register [33, 34], mainly describing
epidemiology. To date, however, most registries still pri-
marily focus on arthroplasty [35, 36]. Therefore, the AO
Foundation developed F.RO.S.T. Prospective data collec-
tion in a structured and systematic manner through the
implementation of a registry will allow physicians to as-
sess the association between different treatment strat-
egies and patient outcomes, including complications. An
important difference between F.R.O.S.T. and previous
studies is that the data collection is extremely detailed,
ranging from information on systemic and local anti-
microbial prophylaxis to implant materials and the use
of standardized outcome measures (e.g., FRI consensus
definition, PROs). Therefore, F.R.O.S.T. could identify
risk factors in more detail, thereby improving strategies
to prevent musculoskeletal adverse events.
In conclusion, although musculoskeletal complications
(e.g., FRI) related to TSFs have already been described in
ancient medical literature, internationally accepted
guidelines regarding preventive measures remain scarce.
While the exact repercussions of this lack of guidelines
on daily clinical practice are unknown, standardized
treatment protocols for TSFs based on scientific evi-
dence are essential to optimize the outcome. The main
purpose of the F.R.O.S.T. registry is to evaluate the asso-
ciation between different treatment strategies and pa-
tient outcomes. It will address not only operation
techniques and implant materials but also perioperative
preventive measures. For the first time, data concerning
systemic perioperative antibiotic prophylaxis, the influ-
ence of local antimicrobials, and timing of soft-tissue
coverage will be collected at an international level and
correlated with standardized outcome measures in a
large prospective, multicenter, observational registry.
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